financetom
Business
financetom
/
Business
/
Update: La-Z-Boy Shares Fall on Downbeat Fiscal Q2 Revenue Outlook, Q1 Adjusted EPS Miss
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: La-Z-Boy Shares Fall on Downbeat Fiscal Q2 Revenue Outlook, Q1 Adjusted EPS Miss
Aug 20, 2025 4:08 AM

05:00 AM EDT, 08/20/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.)

La-Z-Boy ( LZB ) shares were down nearly 25% in recent premarket activity Wednesday as the company issued a downbeat fiscal Q2 sales outlook after its fiscal Q1 earnings fell short of market expectations.

The company reported fiscal Q1 adjusted earnings late Tuesday of $0.47 per diluted share, down from $0.62 a year earlier.

Three analysts polled by FactSet expected $0.53.

Sales for the quarter ended July 26 were $492.2 million, down from $495.5 million a year earlier.

Three analysts expected $490.6 million in a FactSet survey.

The company guided for fiscal Q2 revenue of $510 million to $530 million. Three analysts surveyed by FactSet expect $532.2 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lattice Semiconductor Q3 Adjusted Earnings, Revenue Rise; Q4 Outlook Set
Lattice Semiconductor Q3 Adjusted Earnings, Revenue Rise; Q4 Outlook Set
Nov 3, 2025
04:18 PM EST, 11/03/2025 (MT Newswires) -- Lattice Semiconductor ( LSCC ) reported Q3 adjusted earnings late Monday of $0.28 per diluted share, up from $0.24 a year earlier. Analysts polled by FactSet expected $0.28. Revenue for the three months ended Sept. 27 was $133.3 million, up from $127.1 million a year earlier. Analysts surveyed by FactSet expected $133 million....
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs
Nov 3, 2025
Nov 3 (Reuters) - Vertex Pharmaceuticals ( VRTX ) reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer medicines. The Boston-based company reported total revenue of $3.08 billion for the quarter ended September 30, above analysts' average estimate of $3.05 billion, according to...
Playstudios misses Q3 revenue estimates on softness in casino business 
Playstudios misses Q3 revenue estimates on softness in casino business 
Nov 3, 2025
Overview * Playstudios ( MYPS ) Q3 revenue of $57.6 mln missed analyst expectations * Net loss for Q3 widened to $9.1 mln from $3.1 mln last year * Direct-to-consumer revenue increased by 48% yr/yr in Q3 Outlook * Company expects full-year revenue and AEBITDA below previous guidance due to player activity softness * Company focuses on direct-to-consumer growth and...
Hims and Hers beats revenue estimates on strong subscriber growth
Hims and Hers beats revenue estimates on strong subscriber growth
Nov 3, 2025
(Reuters) -Hims and Hers Health ( HIMS ) beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings. The company and rivals have launched programs that offer personalized versions of semaglutide, the active ingredient in weight-loss drug Wegovy, at doses not accessible through the branded manufacturers, following the government's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved